Related Experiment Video
Updated: Dec 7, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.1K
Starch digestibility modulation significantly improves glycemic variability in type 2 diabetic subjects: A pilot
Anne-Esther Breyton1, Aurélie Goux2, Stéphanie Lambert-Porcheron3
1Centre de Recherche en Nutrition Humaine Rhône-Alpes, Univ-Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, F-CRIN/FORCE Network, 69310, Pierre Bénite, France; Nutrition Research, Mondelez International, 91400, Saclay, France.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|September 29, 2020
Summary
Increasing slowly digestible starch (SDS) in the diet of type 2 diabetes (T2D) patients significantly reduces glucose variability and post-meal glucose spikes. This dietary approach offers a simple nutritional strategy for improved daily glycemic control in T2D management.
Area of Science:
- Nutritional Science
- Endocrinology
- Metabolic Disorders
Background:
- Reducing glycemic variability and postprandial glucose excursions is crucial for managing type 2 diabetes (T2D) complications, beyond HbA1c levels.
- Dietary modification, specifically starch digestibility, is explored as a potential intervention.
Purpose of the Study:
- To investigate if increasing Slowly Digestible Starch (SDS) content in the diet of T2D patients can lower postprandial hyperglycemia and glycemic variability.
- To compare the effects of a high-SDS diet versus a conventional low-SDS diet.
Main Methods:
- A randomized cross-over pilot study involving 8 T2D subjects.
- Participants consumed controlled diets high or low in SDS for one week each.
- Glycemic variability was assessed using a Continuous Glucose Monitoring System.
Main Results:
- The high-SDS diet significantly reduced glycemic variability, indicated by lower Mean Amplitude of Glycemic Excursions (MAGE), Standard Deviation (SD), and Coefficient of Variation (CV).
- Time In Range (TIR) between 140-180 mg/dL was significantly higher with the high-SDS diet.
- Post-meal total Area Under the Curve (tAUC) was significantly lower during the high-SDS diet.
Conclusions:
- A one-week high-SDS diet significantly improves glycemic variability and reduces postprandial glycemic excursions in T2D patients.
- Modulating starch digestibility through diet is a viable nutritional tool for enhancing daily glycemic control in T2D.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
434
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
434
01:22Diabetes Mellitus: Type 2 and Gestational
4.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
428
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
428
01:24Glucagon-like Receptor Agonists
672
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
672
01:06Oral Hypoglycemic Agents: Glinides
467
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
467
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
500
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
500